aTyr Pharma, Inc. (ATYR)
Oxford Ledge is still expanding full research coverage of ATYR. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Atyr Therapeutics develops tRNA synthetase-based therapies for fibrosis and inflammation, with its lead candidate in clinical trials for lung disease.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Delisting / transfer of listing 2026-06-08
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 8-K Results of operations / financial condition; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-11
Source: SEC EDGAR.
Annual results
5 years of annual figures for ATYR, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $190,000 | -$74.1M | -$0.80 |
| 2024 | $235,000 | -$64.0M | -$0.86 |
| 2023 | $353,000 | -$50.4M | -$0.94 |
| 2022 | $10.4M | -$45.3M | -$1.60 |
| 2021 | $0 | -$33.8M | -$1.77 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ATYR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ATYR in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.